Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 19Multiple Myeloma 16Prostatic Neoplasms 14Carcinoma, Non-Small-Cell Lung 12Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma 9Leukemia, Myeloid, Acute 7Lung Neoplasms 6Leukemia, Biphenotypic, Acute 6Squamous Cell Carcinoma of Head and Neck 5Neuroblastoma 5Medulloblastoma 5Lymphoma, Mantle-Cell 5Leukemia 5Hodgkin Disease 5Ependymoma 5Colorectal Neoplasms 5Oropharyngeal Neoplasms 4Neoplasm Metastasis 4Myelodysplastic Syndromes 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Burkitt Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Oligodendroglioma 3Melanoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Glioma 3

Interventions

Temozolomide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × NETWORK × Insulinoma × Clear all
NCT01824875 2026-02-25

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
144 enrolled 15 charts
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡